Advance research for this generation and beyond
Our Therapeutic Focus
While the last decade brought breakthroughs for
some bleeding disorders, people with conditions
that lack available prophylactic therapies have
continued waiting for innovation. These patients
have normalized living with unpredictable bleeds,
limiting their activities and independence. At
Hemab, we believe a different future is
possible—one where prevention, not just
management, becomes the standard of care.
VELORA Pioneer— HMB-002 for Von Willebrand Disease (NCT06754852)
Velora Pioneer is a Phase 1/2 clinical trial of HMB-002 for Von Willebrand Disease (VWD). HMB-002 is being developed as a prophylactic treatment to support restoration of hemostasis in people with VWD using a convenient subcutaneous treatment administration.
VELORA Discover Screening Study for Von Willebrand Disease (NCT06610201)
Velora Discover is a prospective natural history study of patients with Von Willebrand Disease (VWD) to establish baseline disease characteristics, bleeding patterns, and quality of life measures. The purpose of the study is to provide contemporary control data and contextualize treatment effects observed in the interventional components of the Velora Pioneer clinical trial.
Sutacimig for Congenital Factor VII Deficiency (NCT07347249)
This Phase 2 clinical trial evaluates pharmacokinetics, pharmacodynamics, and preliminary safety and tolerability of single ascending doses of sutacimig in patients with Factor VII deficiency. This trial aims to establish proof-of-concept by demonstrating sutacimig’s ability to increase Factor VII levels in patients with Factor VII deficiency.
Sutacimig for Glanzmann Thrombasthenia (NCT06211634)
The goal of this Phase 1/2 clinical trial is to investigate the safety, tolerability, pharmacokinectics, pharmacodynamics and clinical efficacy of stuacimig in patients with Glanzmann thrombasthenia. We have completed the Part A (single ascending dose) and Part B (three-month multiple ascending dose) portions of the trial, and the Part C (long-term extension up to 24 months) portion is currently ongoing.